Baerveldt shunt lowers IOP

Article

Baerveldt shunts effectively lower IOP in eyes with anterior uveal melanoma (AUM) undergoing anterior segment irradiation.

Baerveldt shunts effectively lower IOP in eyes with anterior uveal melanoma (AUM) undergoing anterior segment irradiation.

An investigation, led by Dr Eamon Sharkawi, Hôpital Ophtalmique Jules-Gonin, Université de Lausanne, Switzerland, including 31 eyes with uncontrolled IOP. Each patient underwent anterior segment proton beam radiotherapy (PBRT) and Baerveldt shunt implantation.

Postoperative assessments were conducted on day 1, weeks 1, 3, 6, 9 and months 3, 6, 9 and 12 annually thereafter. IOP that was 21 mm Hg or less was defined as a surgical success, as well as 20% reduction from baseline.

Mean preoperative IOP was recorded at 3.10 mm Hg and mean IOP at the last visit was 15.0 mm Hg. The surgical success rate was 86% after using glaucoma medications. Of the eyes studied, four had minor postoperative complications but there were no local tumour recurrences, systemic metastases or no enucleations caused by ocular hypertension.

The abstract can be found in the British Journal of Ophthalmology.

Related Videos
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Colman Cawe, director of fundraising and communications, Orbis UK
Greg Kunst, CEO of Aurion Biotech
Related Content
© 2023 MJH Life Sciences

All rights reserved.